1. Concise review of lipidomics in nonalcoholic fatty liver disease;Béland-Bonenfant;Diabetes Metab.,2023
2. European Medicines Agency - Committee for Medicinal Products for Human Use Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Chronic Non- Infectious Liver Diseases 2019, 1–22.
3. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease;Kawano;J. Gastroenterol.,2013
4. Vander the histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity;Bricambert;Nat. Commun.,2018